TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.

Lihua E Budde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.